Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK

被引：0
|
作者：
Mughal, F. [1 ]
Barker, J. [2 ]
Cawston, H. [3 ]
Damera, V. [3 ]
Bewley, A. [4 ,5 ]
Morris, J. [6 ]
Shaw, T. [7 ]
Tencer, T. [8 ]
Zhang, F. [8 ]
机构：
[1] Celgene Ltd, Uxbridge, Middx, England
[2] St Johns Inst Dermatol Kings Coll, London, England
[3] Mapi Grp, London, England
[4] Whipps Cross Univ Hosp, London, England
[5] Royal London Hosp, London, England
[6] Cogentia Healthcare Consulting, Cambridge, England
[7] Celgene Ltd, Southall, Middx, England
[8] Celgene Corp, Summit, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2016年 / 175卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [31] Apremilast for the management of moderate to severe plaque psoriasis
    Vangipuram, Ramya
    Alikhan, Ali
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (04) : 349 - 360
  • [32] Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis
    Schmitt-Rau, K.
    Rosenbach, T.
    Radtke, M. A.
    Augustin, M.
    DERMATOLOGY, 2010, 221 (03) : 236 - 242
  • [33] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [34] Apremilast in the therapy of moderate to severe chronic plaque psoriasis and special locations
    Fernandez, Alvaro Barranquero
    Perez, Jorge Alonso Suarez
    Acosta, Enrique Herrera
    Fernandez, Maria Victoria Mendiola
    Ceballos, Enrique Herrera
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB46 - AB46
  • [35] Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB83 - AB83
  • [36] COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A SYSTEMATIC LITERATURE REVIEW
    Sokolova, V
    Tolkacheva, D.
    VALUE IN HEALTH, 2019, 22 : S375 - S376
  • [37] COST-EFFECTIVESS ANALYSIS OF BRODALUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
    Xue, W.
    Gray, E.
    Barbeau, M.
    Khoudigian-Sinani, S.
    Frieder, D.
    VALUE IN HEALTH, 2018, 21 : S240 - S241
  • [38] A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
    Becher, Gabrielle
    Conner, Sophia
    Ingram, Jennifer A.
    Stephen, Karen E.
    McInnes, Alison C.
    Heald, Adrian H.
    Riley, Paul A.
    Davies, Mark
    Domenech, Arnau
    Kasujee, Ismail
    DERMATOLOGY AND THERAPY, 2022, 12 (10) : 2343 - 2354
  • [39] Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subject Treated with Apremilast
    Larson, Emma L.
    DeMeo, Dustin P.
    Young, Andrew B.
    Margevicius, Seunghee
    Rutter, Joseph
    Davies, Amanda L.
    Rohan, Craig A.
    Korman, Neil J.
    Travers, Jeffrey B.
    McCormick, Thomas S.
    Cooper, Kevin D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (09)
  • [40] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Zhang, Jinsui
    Xia, Zemin
    Guo, Wanjie
    Ren, Xiaoxiao
    Liu, Fang
    Ratnaparkhi, Gargi
    Pagada, Amit
    Subramanian, Subhashini
    Hu, Min
    Chen, Wen
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2681 - 2696
12345